Curated News
By: NewsRamp Editorial Staff
November 13, 2026
HeartBeam Q3 2026: Net Loss Narrows to $3M, FDA Breakthrough Status
TLDR
- HeartBeam's narrowed Q3 loss and FDA Breakthrough status position it to capture the portable cardiac monitoring market with superior 3D ECG technology.
- HeartBeam's cable-free device collects 3D ECG signals and synthesizes them into a 12-lead ECG, enabling remote cardiac assessment outside medical facilities.
- HeartBeam's portable 3D ECG technology aims to enable earlier heart attack detection and faster care, potentially saving lives and improving outcomes.
- HeartBeam's 3D ECG tech uses three non-coplanar directions to synthesize a 12-lead ECG, and its pilot study showed higher specificity than standard ECGs.
Impact - Why it Matters
HeartBeam's progress in heart attack assessment, including FDA Breakthrough Device Designation and positive pilot study results, signals a potential paradigm shift in cardiac care. Its portable 3D ECG technology could enable earlier and more accurate detection of heart attacks outside hospitals, reducing time to treatment and improving outcomes. For investors, the narrowed loss and strengthened cash position provide a longer runway to advance pivotal trials, while the regulatory milestones validate the technology's potential. As cardiovascular disease remains a leading cause of death, innovations like HeartBeam's could significantly impact emergency cardiac care and patient survival.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, reported its third-quarter 2026 financial and operational results. The company recorded a net loss of $3 million, or $0.05 per share, compared with a net loss of $5.3 million, or $0.15 per share, in the prior-year period. Operating expenses declined to $3.5 million from $5.3 million, and cash and cash equivalents totaled $6.1 million as of Sept. 30, 2026. HeartBeam also raised approximately $4 million in net proceeds during the fourth quarter through the date of the announcement, bringing pro forma cash to approximately $10.1 million. The company now expects full-year 2026 net operating cash outflow of $12 million to $12.5 million.
Operationally, HeartBeam advanced its strategic focus on heart attack assessment, receiving U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designation and acceptance into the agency’s Total Product Life Cycle Advisory Program (“TAP”). The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms (“ECGs”) with comparable sensitivity. HeartBeam plans to finalize the design of its U.S. pivotal study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027. To view the full press release, visit https://ibn.fm/8CLXO.
HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. For the latest news and updates relating to BEAT, visit the company’s newsroom at https://ibn.fm/BEAT.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Q3 2026: Net Loss Narrows to $3M, FDA Breakthrough Status
